ThinkstockKeryx Biopharmaceuticals Inc. (NASDAQ: KERX) announced on Friday that it had received approval from the FDA on its most recent drug Ferric Citrate, formerly known as Zerenex. The drug is designed to treat low…
Prana Biotechnology saw its shares surge on Friday, on the heels of the FDA granting an orphan drug designation to the company’s PBT2.
Merck & Co. has received approval from the FDA to bring its new drug Keytruda to market.
ThinkstockThe Centers for Medicare and Medicaid Services (CMS) has projected that the current number of uninsured people is expected to decrease. The actuary report signaled that there will also be a faster health care…
Infinity Pharmaceuticals will partner with Abbvie to further develop and commercialize IPI-145, also known as Duvelisib.
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
A new report from the pharmaceutical team at Credit Suisse highlights four top stocks to buy for the remainder of 2014
A Cowen report zeroes in on the most illiquid stocks that will be traded Wednesday as 15 ETFs rebalance.
If the tobacco industry thought it had solved all its legal problems with the introduction of electronic cigarettes, the industry is very likely rethinking its original conclusion.
Jaguar Animal Health has filed with the U.S. Securities and Exchange Commission for an initial public offering.
Calithera Biosciences files with the U.S. Securities and Exchange Commission to conduct an initial public offering.
Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.
Kite Pharma made a big hit in the after-hours market on Monday with its announcement of positive results in a clinical trial.
ThinkstockBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep Vein Thrombosis and Pulmonary Embolisms. Each year an…
ThinkstockWith the biotech space having its usual volatile ups and downs this year, the analysts at Stifel have stepped back into the coverage world and have reinitiated research analysis on some of the top…